From today, prescriptions for Mounjaro – the weekly injection designed to help people lose weight – will be available at GP surgeries across England. The GP Mounjaro rollout is beginning with a cautious and targeted approach. Only those who meet specific health criteria are eligible for now, and not every local practice will be offering it immediately.
Mounjaro, also known as tirzepatide, works by helping people feel fuller for longer, making it easier to eat less. In trials, some patients saw up to 20% reduction in body weight. The treatment has already been used in NHS specialist clinics, but this is the first time it’s being rolled out through local GPs.
To qualify, patients must have a BMI of 40 or above (or 37.5 for people from minority ethnic backgrounds), along with at least four of five conditions: type 2 diabetes, high blood pressure, high cholesterol, cardiovascular disease, and sleep apnoea. Those eligible will also receive wider support, including advice on diet and exercise, but access may depend on the services available in each area.
The phased rollout aims to manage GP workload and NHS resources while focusing on those who are most at risk. Some GP surgeries are already asking patients not to book appointments unless they meet the strict criteria, as the rollout will take time to scale up.
Demand is expected to be high. Many GPs will require additional training before prescribing Mounjaro, and the medicine involves close monitoring, especially during the early stages. Monthly check-ups are needed at first, and patients must be supported with lifestyle advice alongside the treatment.
Some people won’t be suitable for Mounjaro at all – for instance, those who are pregnant, breastfeeding, or have certain medical conditions. Anyone interested will need to speak to their doctor or check with their local NHS service for further guidance.
While the current phase targets a relatively small group, the rollout is expected to expand. From mid-2026, eligibility may extend to more people with lower BMI thresholds. By 2027, the criteria could be relaxed further, with up to 3.4 million people potentially benefiting over the next decade.
Other options remain available in the meantime. NHS-supported programmes, lifestyle apps, and local weight-loss services continue to offer help for people wanting to manage their health without medication.
Mounjaro can also be accessed privately in some pharmacies and clinics, but prices remain high and appointments limited. The NHS rollout will bring the treatment to those who need it most, free at the point of access.
The GP Mounjaro rollout marks a new stage in how the NHS is tackling obesity. It won’t be instant or universal, but it’s a shift towards treating weight-related illness in community settings, not just in specialist clinics. Patients who think they may qualify should check their local NHS website or speak to their GP when services become available.
For more on health access and local updates in the capital, visit EyeOnLondon.
Follow us on:
Subscribe to our YouTube channel for the latest videos and updates!
We value your thoughts! Share your feedback and help us make EyeOnLondon even better!
